Bullishwave
Bullish Charts - Huge Earrings BeatDURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Zogenix, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.
This morning Durect reported earrings that blew away Wall Street Estimates.
Q2 EPS $0.07 Up From $(0.04) YoY, Sales $25 Million Beat $11.48 Million Estimate
Sales more than doubled estimates.
Daily Chart is Bullish
Indicators are rising, Bullish
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
Bullish Charts - Golden Cross, Possible BuyoutCloudera, Inc. provides a suite of data analytics and management products in the United States, Europe, and Asia. The company operates through two segments, Subscription and Services. It offers Cloudera Enterprise Data Hub that allows companies to execute various analytic functions against a shared set of governed and secures data in public and private clouds, and data centers; Cloudera Data Warehouse, a hybrid cloud solution for self-service analytics; Cloudera Data Science and Engineering enables users to streamline, simplify, and scale big data processing; and Cloudera Operational DB that enables stream processing and real-time analytics on continuously changing data. The company also provides Hortonworks Data Platform, a data management platform that helps organizations to securely store, process, and analyze various data assets; Cloudera DataFlow, a data platform that collects, curates and analyzes data; Cloudera Data Science Workbench that enables self-service data science for the enterprise; and Cloudera Altus, a platform-as-a-service offering In addition, it offers Cloudera SDX, a solution that enables common security, governance, lineage, and metadata management for multiple analytics functions; and Cloudera Workload XM, an analytic workload experience management cloud service. Further, the company provides consulting, professional, and education services. It serves corporate enterprises and public sector organizations primarily through its direct sales force. The company was founded in 2008 and is headquartered in Palo Alto, California.
Daily Chart:
Volume: Bullish
PMO: Bullish
MACD: Bullish
RSI: Bullish
Stochastic: Bullish
OBV: Bullish
Accumulation: Bullish
Sector: Bullish
50-Day MA just crossed the 100-Day MA and the 200-Day MA - Bullish
Search through the recent news, there has been a lot of talk about Cloudera being bought for as high as $18.00 a share. IBM was mentioned as a potential buyer of the company.
Market got crushed today, Cloudera was up. - Bullish
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
BITCOIN SQUEEZE??!!Price Action (Technical Analysis): Top-Down Analysis on Bitcoin for this Week, i'm expecting big plays pushing up from Bitcoin with all the doubt in the US Dollar with the Dollar Index not holding up very well and with the Greenbacks economy not at its very best of right now until next month.
Fundamental Analysis: None.